Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914036 | 0.82 | MEN1 (0.51) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL27895804 | 0.80 | MEN1 (0.50) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL28158210 | 0.78 | MEN1 (0.49) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL28157934 | 0.77 | MEN1 (0.48) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL2228050 | 0.77 | MEN1 (0.48) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL14834351 | 0.77 | KDM1A (0.43) | KMT2ANPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL10965323 | 0.76 | MEN1 (0.47) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL2228112 | 0.74 | AURKA (0.59) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL21676894 | 0.73 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9AROCK1 | |
| SCHEMBL19701004 | 0.73 | NUDT1 (0.51) | KMT2AMEN1NPC1RAB9AROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2019-03-05 | — | — | US | disclosed |
| EP-3237418-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3237418-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-6599910-B1 | Inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| EP-1112070-A4 | NOVEL SUBSTITUTED TRIAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1112070-A1 | NOVEL SUBSTITUTED TRIAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000010563-A1 | NOVEL SUBSTITUTED TRIAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5494887-A | Ring annulated 5-alkoxy-n-aryl[1,2,4]triazolo[1,5-C]-pyrimidine-2-sulfonamide herbicides | DOWELANCO (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0343752-B1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DOWELANCO (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5163995-A | For use with grassy crops and soybeans | DOWELANCO (US) | 1992-11-17 | — | — | US | disclosed |
| US-5010195-A | From 5-alkoxy-1,2,4-triazolo(1,5-c)pyrimidine | THE DOW CHEMICAL COMPANY (US) | 1991-04-23 | — | — | US | disclosed |
| WO-1989011782-A1 | ALKOXY-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE-2-SULFONAMIDES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES | THE DOW CHEMICAL COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0343752-A1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DowElanco (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | KMT2A 27/4885MEN1 1351/4885NPC1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.